Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03146650
Recruitment Status : Recruiting
First Posted : May 10, 2017
Last Update Posted : August 14, 2018
Bristol-Myers Squibb
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Northwestern University

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : July 2021
  Estimated Study Completion Date : June 2022